VB Spine appoints Thomas E. Oglesby as CFO; Vor Bio issues employee stock grants

VB Spine LLC has appointed Thomas E. Oglesby as its new Chief Financial Officer, effective September 16, 2026. Oglesby, a veteran medtech finance executive, previously held leadership roles at Zimmer Biomet and Medtronic. In his new capacity, he will oversee the finance organization and assist the executive team with strategy, capital allocation, and the expansion of the company’s spine portfolio.

Separately, biotechnology company Vor Bio announced that its Compensation Committee granted stock options and restricted stock units to nine new employees on October 1, 2026. These grants, totaling 59,250 stock options and 12,550 restricted stock units, were issued as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).